09:37 ETIPA Urges SEC to Complete National Framework for Registered Offeringsprnewswire·16 hours agoIPA0.00%IYR+0.58%
08:45 ETThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath Itprnewswire·Jun 16 at 07:45 AMHYFT-5.56%
FDA Grants Orphan Drug Designation To OSE's Pegrizeprument For Post-Heart Transplant Rejectionnasdaq·Apr 27 at 06:15 AMIPA0.00%LYEL+0.23%
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid TumorsMorningStar·Apr 19 at 04:40 PMIPA0.00%BBH+2.95%
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 MeetingGlobeNewswire·Apr 15 at 12:30 AMIPA0.00%MLTX-5.89%
Fusion Antibodies Sells Antibody IP to Finn Therapeutics in £250,000 DealTip Ranks·Mar 30 at 01:38 AMIPA0.00%
OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing.Unusual Whales·Mar 2 at 11:01 AMARKG+8.00%IPA0.00%
09:08 ET Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Researchprnewswire·Jan 21 at 08:08 AMBBH+2.95%FBT+1.85%
ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on MondayMarket Beat·Sep 9, 2025 at 12:24 AMIPA0.00%
